BioNTech estimates it will be able to manufacture 2 billion doses in 2021

BioNTech estimates it will be able to manufacture 2 billion doses in 2021

Frankfurt | German biotechnology company BioNTech on Monday estimated it would be able to produce “2 billion doses” of the COVID-19 vaccine by the end of 2021, significantly more than the previous target of 1.3 billion doses.

• Read also: All the developments of the pandemic

The German SME, associated with the American giant Pfizer, arrived at this new estimate taking into account the “new standard” allowing the administration of 6 doses per vial instead of 5, according to a document posted on its website. BioNTech is also counting on “the expansion of its current facilities”, including the commissioning, expected in February, of another European production site, in Marburg, Germany.

Share Button